Scholarlink

Purpose of Review <p>This literature review explores the disposition mechanisms contributing to buprenorphine’s elevated exposure in oral fluids compared to other medications used in opioid use disorder (OUD) treatment, with a focus on its impact on oral health in patients undergoing medication-assisted treatment. It specifically assesses how buprenorphine’s lipophilicity, potential active transport mechanisms, ion-trapping potential, and interaction with GABAergic pathways contribute to the oral health risks associated with its administration. Understanding these mechanisms may provide insights into minimizing buprenorphine’s negative effects on dental health while preserving its therapeutic efficacy.</p> Recent Findings <p>Buprenorphine’s pharmacokinetic properties, including its lipophilicity, facilitate prolonged retention in oral tissues following sublingual or buccal administration. Its weakly basic properties promote potential ion-trapping in oral epithelial tissues, further sustaining buprenorphine exposure in oral fluids. Recent evidence also suggests that active transport mechanisms, such as P-glycoprotein, may influence&#xa0;buprenorphine’s&#xa0;accumulation within salivary glands. Together, these factors elevate the risk of enamel demineralization, xerostomia, and dental caries. Additionally, buprenorphine’s interaction with GABAergic pathways may significantly reduce salivary secretion, further exacerbating oral health risks.</p> Summary <p>An improved understanding of buprenorphine’s oral disposition mechanisms is essential to comprehensively address the oral health risks associated with its therapeutic use. Clarifying these pharmacokinetic processes can inform clinical practices, optimize drug delivery methods, and effectively mitigate adverse effects highlighted by recent FDA warnings. Future research, guided by these insights, should focus on clinical strategies that preserve buprenorphine’s therapeutic efficacy while substantially reducing its detrimental impact on patients’ oral health outcomes, ultimately improving patient adherence and addiction recovery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disposition Factors Impacting Buprenorphine Salivary Gland Accumulation and Oral Fluid Exposure

  • 期刊论文

  • 发表日期：

    2025年5月30日

查看全文
  • Cody W. Yu,
  • Rongjin Sun,
  • Ming Hu

摘要

Purpose of Review

This literature review explores the disposition mechanisms contributing to buprenorphine’s elevated exposure in oral fluids compared to other medications used in opioid use disorder (OUD) treatment, with a focus on its impact on oral health in patients undergoing medication-assisted treatment. It specifically assesses how buprenorphine’s lipophilicity, potential active transport mechanisms, ion-trapping potential, and interaction with GABAergic pathways contribute to the oral health risks associated with its administration. Understanding these mechanisms may provide insights into minimizing buprenorphine’s negative effects on dental health while preserving its therapeutic efficacy.

Recent Findings

Buprenorphine’s pharmacokinetic properties, including its lipophilicity, facilitate prolonged retention in oral tissues following sublingual or buccal administration. Its weakly basic properties promote potential ion-trapping in oral epithelial tissues, further sustaining buprenorphine exposure in oral fluids. Recent evidence also suggests that active transport mechanisms, such as P-glycoprotein, may influence buprenorphine’s accumulation within salivary glands. Together, these factors elevate the risk of enamel demineralization, xerostomia, and dental caries. Additionally, buprenorphine’s interaction with GABAergic pathways may significantly reduce salivary secretion, further exacerbating oral health risks.

Summary

An improved understanding of buprenorphine’s oral disposition mechanisms is essential to comprehensively address the oral health risks associated with its therapeutic use. Clarifying these pharmacokinetic processes can inform clinical practices, optimize drug delivery methods, and effectively mitigate adverse effects highlighted by recent FDA warnings. Future research, guided by these insights, should focus on clinical strategies that preserve buprenorphine’s therapeutic efficacy while substantially reducing its detrimental impact on patients’ oral health outcomes, ultimately improving patient adherence and addiction recovery.